Pharmaceutical company China Pharma Holdings Inc (NYSE American: CPHI) announced on Monday that it anticipates launching its patented Dry Eye Disease Therapeutic Device in China during the first quarter of 2025 through its subsidiary, Hainan Helpson Medical and Biotechnology Co, Ltd.

The device, designed to treat dry eye disease, has completed production commissioning and third-party testing, following China Pharma's acquisition of the technology in late 2022.

Dry eye disease affects approximately 400 million people in China, with an incidence rate of 21%-30%, second only to myopia. The market for dry eye treatments in China is projected to grow at a compound annual growth rate (CAGR) of 6.04% through 2030, potentially reaching a market size of USD579.51m.

The device uses ophthalmic oxygen-enriched atomization technology to spray oxygen-rich droplets onto the eye surface, improving moisture, oxygen supply and tear fluid stability. This physical therapy offers a drug-free alternative with enhanced effectiveness and comfort.

China Pharma focuses on high-incidence and high-mortality conditions in China, leveraging its GMP-certified product lines and nationwide distribution network.